(Q40521494)

21 September 2017

FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells (English)

1 reference

21 September 2017

1 reference

Maria Rita Rippo

1

1 reference

21 September 2017

Simona Moretti

2

1 reference

21 September 2017

Silvia Vescovi

3

1 reference

21 September 2017

Marco Tomasetti

4

1 reference

21 September 2017

Sara Orecchia

5

1 reference

21 September 2017

Giuseppe Amici

6

1 reference

21 September 2017

Alfonso Catalano

7

1 reference

21 September 2017

Antonio Procopio

8

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

21 September 2017

1 reference

21 September 2017

23

1 reference

21 September 2017

7753-7760

1 reference

21 September 2017

47

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1208051

21 September 2017

0 references

cites work

Pathology of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Regulation of apoptosis by lethal cytokines in human mesothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

The TRAIL to selective tumor death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Defective death receptor signaling as a cause of tumor immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Treatment of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Asbestos fibres inhibit the in vitro activity of ymphokine-activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Mesothelial cells: their structure, function and role in serosal repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

The inhibition of apoptosis in myositis and in normal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

The CD95(APO-1/Fas) DISC and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Chemotherapy for malignant pleural mesothelioma: past results and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Small RNA: can RNA interference be exploited for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

7 January 2021

Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

7 January 2021

High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

7 January 2021

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208051

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1208051

1 reference

Dimensions Publication ID

21 September 2017

0 references

1 reference